GlobeNewswire·Apr 7, 2026, 6:00 AM ET

Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit

Serina Therapeutics announced that Chief Development Officer Randall Moreadith, MD, PhD, will present at the 5th LNP Formulation & Process Development Summit in Boston on April 7, 2026.
The presentation will feature data on novel lipid nanoparticles built entirely on Serina's POZ Platform to address the immunogenicity dilemma associated with standard PEG-lipids.
Preclinical rat studies showed that the POZ-lipid failed to elicit an antibody response, unlike standard PEG-lipids which trigger IgM & IgG responses & are linked to serious adverse events.
Serina is advancing a replacement strategy for ionizable lipids, another essential LNP component implicated in safety concerns.
Preliminary results include a novel polymer-lipid designed to bind a broad range of oligonucleotide payloads.
Serina's proprietary POZ Platform utilizes poly(2-oxazoline), a synthetic water-soluble polymer, to improve drug loading control & release precision for subcutaneous injections.
The POZ Platform aims to enhance the efficacy & safety profiles of small molecules, RNA-based therapeutics, & antibody-based drug conjugates.
Pfizer holds a non-exclusive license agreement to utilize Serina's POZ polymer technology for lipid nanoparticle drug delivery formulations.
Serina is headquartered in Huntsville, Alabama, on the campus of the HudsonAlpha Institute of Biotechnology.